Name | N4 Pharma |
---|---|
Epic | N4P |
Isin | GB00BYW8QM32 |
Industry | Pharmaceuticals & Biotechnology |
Latest share price | 0.63p | Net gearing | n/a |
---|---|---|---|
Market capitalisation | £2.50 | Debt ratio | n/a |
Shares in issue | 268.78 | Debt-to-equity ratio | n/a |
P/E ratio | n/a | Assets / equity ratio | n/a |
Total dividends per share | n/a | Price to book value | n/a |
Dividend yield | n/a | ROCE | -57.14 |
Dividend cover | n/a | EPS growth | n/a |
Earning per share | -0.55 | 52-week high / low | 0.50p / 3.07p |
Type | Ex-date | Pay-date | Net-dividend |
---|---|---|---|
No dividends declared |
Company name | N4 Pharma |
---|---|
Address | 6th Floor, 60 Gracechurch Street, London, United Kingdom, EC3V 0HR |
Telephone | |
Website | http://www.n4pharma.com/ |
Director | Position |
---|---|
Mr Nigel Theobald | CEO |
Mr Luke Cairns | Executive Director |
Mr David Templeton | Executive Director |
Dr Chris Britten | Non-Executive Chairman |
Assets £ (m) | 2022 | 2021 | 2020 |
---|---|---|---|
Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
Intangible asssets and goodwill | n/a | n/a | n/a |
Investments and other non-current assets | n/a | n/a | n/a |
Total non-current assets | n/a | n/a | n/a |
Inventory / work in progress | n/a | n/a | n/a |
Trade and other receivables | 0.25 | 0.56 | 0.27 |
Cash and equivalents | 1.92 | 1.78 | 3.56 |
Other current assets and asset held for resale | n/a | n/a | n/a |
Total of all assets | 2.17 | 2.34 | 3.83 |
Liabilities £ (m) | 2022 | 2021 | 2020 |
---|---|---|---|
Short term liabilities | 0.08 | 0.21 | 0.17 |
Long term liabilities | n/a | n/a | n/a |
Other liabilites / pension etc | n/a | n/a | n/a |
Total of all liabilities | 0.08 | 0.21 | 0.17 |
Net assets £ (m) | 2022 | 2021 | 2020 |
---|---|---|---|
Net assets | 2.09 | 2.13 | 3.66 |
Equity £ (m) | 2022 | 2021 | 2020 |
---|---|---|---|
Share capital | 9.21 | 9 | 9 |
Minority interests | n/a | n/a | n/a |
Retained earnings | -8.06 | -7.03 | -5.49 |
Share premium account | 14.7 | 13.95 | 13.95 |
Total equity | 2.09 | 2.13 | 3.66 |
Income £ (m) | 2022 | 2021 | 2020 |
---|---|---|---|
Turnover | n/a | n/a | n/a |
Operating profit | -1.19 | -1.84 | -1.56 |
Pre-tax profit | -1.19 | -1.84 | -1.57 |